Meperidine
As of the edition of 20 October 2026, Meperidine is a small molecule: marketed, first approved in 1947 (CH); acts on OPRM1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Demerol
- First approved
- 22 January 1947 (CH)
- Approvals on record
- 14 in 3 regions
- Holder of the most recent approval
- Quagen Pharmaceuticals; 5 holders in all
- Registered trials
- 25, 2 stopped early
- Disease areas
- Nervous system; Cancer; Digestive system; Pregnancy and women's health; Urinary and reproductive; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Meperidine.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| OPRM1 | Mu-type opioid receptor | P35372 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 8 | 0 | 0 |
| Phase 1 | 3 | 1 | 1 | 1 |
| Phase 2 | 3 | 2 | 0 | 0 |
| Phase 3 | 3 | 1 | 0 | 1 |
| Phase 4 | 7 | 7 | 0 | 0 |
| All trials | 25 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Acquired holder | 2005 to now |
| Quagen Pharmaceuticals | Acquired holder | 2024 to now |
| Abbott | Later holder | |
| Sanofi | Earlier holder |